Drugs / measles-mumps-rubella vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05952505 | Aug → Dec 2023 | COVID-19, chickenpox, measles, mumps infectious disease +1 | Shanghai Municipal Center for Disease Control and Prevention | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | measles-mumps-rubella vaccine | “measles-mumps-rubella vaccine(MMR) in day 28” NCT05952505 ↗ |
| Known as | MMR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05952505 ↗ |
| Modality | Vaccine | “measles-mumps-rubella vaccine(MMR)” NCT05952505 ↗ |